BIOMAT Database Logo BIOMAT Database Logo

Serum-soluble IL-2 receptor and IL-6 levels in patients with melanoma. 1997

M D Boyano, and M D García-Vázquez, and J Gardeazabal, and A García de Galdeano, and I Smith-Zubiaga, and M L Cañavate, and J A Raton, and I Bilbao, and J L Díaz-Pérez
Department of Cell Biology and Morphological Sciences, School of Medicine and Dentistry, University of the Basque Country, Leioa, Spain. gcpbolom@lg.ehu.es

Elevated soluble IL-2 receptor (sIL-2R) and IL-6 serum concentrations have been reported as adverse prognostic factors in several types of cancer. In order to determine whether these factors are predictive of metastatic progression in melanoma, sIL-2R and IL-6 levels were measured in sera from 172 patients with melanoma and 60 in healthy controls. Mean sIL-2R values were significantly higher in the patients than in normal controls and the highest values were observed in those that developed metastasis during follow-up. However, no correlation was found with the stage of the disease. Serum IL-6 levels were found to be correlated with age and sex, but not correlated with sIL-2R levels. Statistical analysis was based on logistic and Cox regression models. The factors considered were age, sex, stage, disease-free interval and serum sIL-2R and IL-6 levels. The analysis showed that only the sIL-2R value is significantly linked to metastatic progression. This finding suggests that high serum levels of sIL-2R could be a predictive factor of metastatic progression in malignant melanoma.

UI MeSH Term Description Entries
D008297 Male Males
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

M D Boyano, and M D García-Vázquez, and J Gardeazabal, and A García de Galdeano, and I Smith-Zubiaga, and M L Cañavate, and J A Raton, and I Bilbao, and J L Díaz-Pérez
Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis.
February 1998, The Journal of rheumatology,
M D Boyano, and M D García-Vázquez, and J Gardeazabal, and A García de Galdeano, and I Smith-Zubiaga, and M L Cañavate, and J A Raton, and I Bilbao, and J L Díaz-Pérez
Soluble interleukin 6 (IL-6) receptor and IL-6 levels in serum and synovial fluid of patients with different arthropathies.
November 1997, The Journal of rheumatology,
M D Boyano, and M D García-Vázquez, and J Gardeazabal, and A García de Galdeano, and I Smith-Zubiaga, and M L Cañavate, and J A Raton, and I Bilbao, and J L Díaz-Pérez
Soluble IL-6 receptor levels in AML patients.
April 2000, Cytokine,
M D Boyano, and M D García-Vázquez, and J Gardeazabal, and A García de Galdeano, and I Smith-Zubiaga, and M L Cañavate, and J A Raton, and I Bilbao, and J L Díaz-Pérez
Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis.
May 1994, The Journal of clinical investigation,
M D Boyano, and M D García-Vázquez, and J Gardeazabal, and A García de Galdeano, and I Smith-Zubiaga, and M L Cañavate, and J A Raton, and I Bilbao, and J L Díaz-Pérez
Interleukin 6 (IL-6) and soluble IL-2 receptor levels in patients with rheumatoid arthritis treated with low dose oral methotrexate.
February 1995, The Journal of rheumatology,
M D Boyano, and M D García-Vázquez, and J Gardeazabal, and A García de Galdeano, and I Smith-Zubiaga, and M L Cañavate, and J A Raton, and I Bilbao, and J L Díaz-Pérez
[Serum levels of soluble Fas soluble Fas ligand and soluble IL-2 receptor in patients with coronary heart disease]
August 2002, Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences,
M D Boyano, and M D García-Vázquez, and J Gardeazabal, and A García de Galdeano, and I Smith-Zubiaga, and M L Cañavate, and J A Raton, and I Bilbao, and J L Díaz-Pérez
Serum levels of soluble IL-2 receptor alpha, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration.
May 1999, Schizophrenia research,
M D Boyano, and M D García-Vázquez, and J Gardeazabal, and A García de Galdeano, and I Smith-Zubiaga, and M L Cañavate, and J A Raton, and I Bilbao, and J L Díaz-Pérez
Soluble IL-2 receptor levels in patients with Graves' ophthalmopathy.
June 1992, Clinical and experimental immunology,
M D Boyano, and M D García-Vázquez, and J Gardeazabal, and A García de Galdeano, and I Smith-Zubiaga, and M L Cañavate, and J A Raton, and I Bilbao, and J L Díaz-Pérez
[Soluble IL-2 receptor levels in patients with Graves' ophthalmopathy].
June 1999, Yan ke xue bao = Eye science,
M D Boyano, and M D García-Vázquez, and J Gardeazabal, and A García de Galdeano, and I Smith-Zubiaga, and M L Cañavate, and J A Raton, and I Bilbao, and J L Díaz-Pérez
Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease.
August 1996, The Journal of clinical endocrinology and metabolism,
Copied contents to your clipboard!